Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Waters Solutions Now Shipping with UNIFI 1.6

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
UNIFI 1.6 is industry’s first multi-user, server-based technology for management of analytical LC, LC/MS, and LC/MS/MS data.

Waters Corporation is now shipping UNIFI® Scientific Information System, release version 1.6, for the Waters® Biopharmaceutical Platform Solution, Regulated Bioanalysis Platform Solution, Screening Platform Solution, Pesticide Screening Application Solution and Metabolite Identification Application Solution.

UNIFI 1.6 features improved software performance, default and customizable workflows capabilities, and multi-user server-based connectivity.

“With industry-leading core technology positions in separations, detection, chemistries, and informatics, Waters is uniquely positioned to develop systems that optimize technology performance for dedicated application areas,” said Dr. Rohit Khanna, Vice President of Informatics and Worldwide Marketing for the Waters Division.

Dr. Khanna continued, “With each release of UNIFI, we are working and collaborating with customers to guide development of future platform and application solutions. The expansion of UNIFI-based solutions is an evolutionary process that is proving successful for our customers.”

With version 1.6, UNIFI significantly expands its available laboratory footprint from a single workstation to support multi-user, server-based workgroups for the capture, storage, and management of analytical LC, LC/MS, and LC/MS/MS data across applications.

Additionally with this release, UNIFI advances its ability to manage and store exponentially larger dataset files with improved robustness, performance, and processing speed.

“This is major step forward towards Waters’ vision for UNIFI as an enterprise-wide Scientific Information System,” continued Dr. Khanna.

“UNIFI’s workgroup configuration is designed to support multiple scientists …within a common software environment. From acquisition to data interpretation to reporting, UNIFI comprehensively captures scientific workflow. UNIFI offers laboratory-dependent organizations improved abilities to unite the knowledge and improve productivity of their researchers.”

Biopharmaceutical Platform Solution with UNIFI™ is a targeted total solution for developers of biotherapeutics and biosimilars. The system solution consists of the ACQUITY UltraPerformance LC® (UPLC®) H-Class, the Xevo® G2-S QT of mass spectrometer, Waters’ application-tested bioseparation column chemistries, and analytical standards.

Regulated Bioanalysis Platform Solution with UNIFI is an LC/MS/MS system for drug metabolism and pharmacokinetic (DMPK) organizations and CROs that combines the latest in sample preparation, UPLC and chemistries, and tandem quadrupole mass spectrometry.

Screening Platform Solution with UNIFI is the first and only comprehensive screening solution to target, identify, quantify and review based on a streamlined analytical workflow that enables more accurate results across a variety of applications. The holistically designed Platform Solution consists of the ACQUITY UPLC I-Class, the Xevo G2-S QT of mass spectrometer, Waters Analytical Standards & Reagents and Waters Chemistries.

Pesticide Screening Application Solution with UNIFI delivers the ease-of-use, sensitivity, stability, reproducibility, and throughput scientists need to successfully and profitably perform pesticide residue screening in a manner compliant with regulatory requirements today and in the future.

Metabolite Identification Application Solution with UNIFI is the world’s most comprehensive metabolite identification system assisting the DMPK scientist in identifying and characterizing metabolites in both discovery and development environments. Chemically intelligent yet flexible workflows are at the core of UNIFI’s design. The workflow approach integrates both quantitative and qualitative datasets and workflows into a single analysis.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Waters and Ireland's NIBRT Partner on Training and Research
The partnership will increase large molecule characterization capacity and knowledge, helping to deliver new, more effective therapeutic options.
Thursday, September 27, 2012
Waters Selects Prof. Pauline Rudd for Center of Innovation Program Honors
Waters-NIBRT partnership advances biopharmaceutical research, characterization and training.
Friday, April 06, 2012
Waters, Ireland’s NIBRT Partner on Training and Research to Advance Burgeoning Biopharma Industry
Will increase large molecule characterization capacity and knowledge, help deliver new, more effective therapeutic options.
Tuesday, April 03, 2012
Waters and Tecan Sign Agreement for Clinical Assay Platform
The agreement will address the growing need for greater efficiencies and throughput that can be obtained with the automation of routine clinical laboratory assays.
Wednesday, January 18, 2012
Scientific News
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!